Logotype for Nakanishi Inc

Nakanishi (7716) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Nakanishi Inc

Q2 2026 earnings summary

7 Aug, 2026

Executive summary

  • Achieved double-digit sales growth across all business segments, with notable strength in Japan's Dental and Surgical businesses and all segments posting double-digit revenue growth.

  • Consolidated net sales rose 20.5% year-over-year to ¥47,234 million, supported by yen depreciation and M&A contributions from Acra Cut and Intech.

  • EBITDA increased 22.9% year-over-year to ¥12,769 million, with operating income up 32.0% to ¥10,012 million and net income attributable to owners of parent up 132.0% to ¥8,144 million.

  • Full-year financial forecast revised upward, with operating, ordinary, and net profit expected to reach record highs (excluding prior year one-off gains).

  • Enhanced shareholder returns with a higher share repurchase limit and a two-for-one stock split effective October 1, 2026.

Financial highlights

  • Q2 FY2026 net sales: ¥47,234M (+20.5% YoY); gross profit: ¥27,424M (+18.7% YoY); EBITDA: ¥12,769M (+22.9% YoY); operating profit: ¥10,012M (+32.0% YoY); net profit: ¥8,144M (+132.0% YoY); EPS: ¥98.07 (+67.1% YoY).

  • Forex impact added ¥2,884M to net sales YoY.

  • All segments posted double-digit sales growth: Dental (+14.6%), DCI (+23.6%), Surgical (+53.4%), Industrial (+28.6%).

  • Regional sales growth: Japan (+25.2%), North America (+25.7%), Europe (+23.2%), Asia (+9.8%), Others (+4.2%).

  • Total assets increased to ¥174,551M, and net assets to ¥122,009M as of June 30, 2026.

Outlook and guidance

  • FY2026 net sales forecast revised to ¥94,480M (+16.4% YoY); EBITDA ¥24,340M (+22.3% YoY); operating profit ¥16,215M (+15.0% YoY); net profit ¥13,544M (+21.0% YoY).

  • EPS forecast for FY2026 is ¥81.55 post-stock split (¥163.10 pre-split).

  • Assumed exchange rates: ¥155/USD, ¥180/EUR for 2H.

  • All business segments expected to continue growth, with Dental and DCI leading.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more